|Title:||Genetic diversity and antigenic polymorphism in plasmodium falciparum: Extensive serological cross-reactivity between allelic variants of merozoite surface protein 2.|
|Keywords:||EMTREE drug terms: antigen; antimalarial agent; epitope; merozoite surface protein 2; merozoite surface protein 2 vaccine; unclassified drug; vaccine EMTREE medical terms: allele; antibody response; article; child; cross reaction; DNA polymorphism; female; genetic selection; genetic variability; genotype; human; immune response; immunity; malaria; newborn; nucleotide sequence; Plasmodium falciparum; priority journal; serotype|
|Citation:||Franks, S., Baton, L., Tetteh, K., Tongren, E., Dewin, D., Akanmori, B. D., . . . Riley, E. M. (2003). Genetic diversity and antigenic polymorphism in plasmodium falciparum: Extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infection and Immunity, 71(6), 3485-3495|
|Abstract:||Diversity in the surface antigens of malaria parasites is generally assumed to be a mechanism for immune evasion, but there is little direct evidence that this leads to evasion of protective immunity. Here we show that alleles of the highly polymorphic merozoite surface protein 2 (MSP-2) can be grouped (within the known dimorphic families) into distinct serogroups; variants within a serogroup show extensive serological cross-reactivity. Cross-reactive epitopes are immunodominant, and responses to them may be boosted at the expense of responses to novel epitopes (original antigenic sin). The data imply that immune selection explains only some of the diversity in the msp-2 gene and that MSP-2 vaccines may need to include only a subset of the known variants in order to induce pan-reactive antibodies.|
|Appears in Collections:||Noguchi Memorial Institute for Medical Research|
Items in UGSpace are protected by copyright, with all rights reserved, unless otherwise indicated.